Combination treatment for resistant immune thrombocytopenia (ITP)
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with immune thrombocytopenia (ITP), meaning other causes of low platelets have been ruled out.
- Your platelet count is below 30 (a measure of blood clotting cells) at the time you join the study.
- You did not get a lasting improvement from a full course of steroids taken for at least 4 weeks, or your platelet count dropped again when steroids were reduced or stopped.
- You do not have low platelets caused by another condition like HIV, hepatitis C, H. pylori, or lupus.
- You have not been treated with rituximab in the past.
- You are not pregnant or nursing, and you do not have heart failure, severe irregular heartbeat, active cancer, or significant liver or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.